Unknown

Dataset Information

0

Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1? and HIF-2? target genes.


ABSTRACT:

Background

Activating KRAS mutations are important for cancer initiation and progression; and have recently been shown to cause primary resistance to therapies targeting the epidermal growth factor receptor. Therefore, strategies are currently in development to overcome treatment resistance due to oncogenic KRAS. The hypoxia-inducible factors-1? and -2? (HIF-1? and HIF-2?) are activated in cancer due to dysregulated ras signaling.

Methods

To understand the individual and combined roles of HIF-1? and HIF-2? in cancer metabolism and oncogenic KRAS signaling, we used targeted homologous recombination to disrupt the oncogenic KRAS, HIF-1?, and HIF-2? gene loci in HCT116 colon cancer cells to generate isogenic HCT116WT KRAS, HCT116HIF-1?-/-, HCT116HIF-2?-/-, and HCT116HIF-1?-/-HIF-2?-/- cell lines.

Results

Global gene expression analyses of these cell lines reveal that HIF-1? and HIF-2? work together to modulate cancer metabolism and regulate genes signature overlapping with oncogenic KRAS. Cancer cells with disruption of both HIF-1? and HIF-2? or oncogenic KRAS showed decreased aerobic respiration and ATP production, with increased ROS generation.

Conclusion

Our findings suggest novel strategies for treating tumors with oncogenic KRAS mutations.

SUBMITTER: Chun SY 

PROVIDER: S-EPMC2999617 | biostudies-literature | 2010 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes.

Chun Sang Y SY   Johnson Craig C   Washburn Joseph G JG   Cruz-Correa Marcia R MR   Dang Duyen T DT   Dang Long H LH  

Molecular cancer 20101113


<h4>Background</h4>Activating KRAS mutations are important for cancer initiation and progression; and have recently been shown to cause primary resistance to therapies targeting the epidermal growth factor receptor. Therefore, strategies are currently in development to overcome treatment resistance due to oncogenic KRAS. The hypoxia-inducible factors-1α and -2α (HIF-1α and HIF-2α) are activated in cancer due to dysregulated ras signaling.<h4>Methods</h4>To understand the individual and combined  ...[more]

Similar Datasets

| S-EPMC8335704 | biostudies-literature
| S-EPMC3362092 | biostudies-literature
| S-EPMC9027058 | biostudies-literature
| S-EPMC4941367 | biostudies-literature
| S-EPMC3472002 | biostudies-literature
| S-EPMC8648997 | biostudies-literature
| S-EPMC4163527 | biostudies-literature
| S-EPMC4823026 | biostudies-literature
| S-EPMC2811371 | biostudies-literature
| S-ECPF-GEOD-27523 | biostudies-other